Navigation Links
John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting
Date:7/18/2011

pen-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis.

David S. Siegel, M.D., Ph.D. and colleagues presented findings from a phase II, single-arm open-label study of carfilzomib (CFZ), a novel, highly selective proteasome inhibitor in development for treatment of advanced multiple myeloma. Proteasome inhibitors block the actions of certain proteins (proteasomes) that cancer cells need to survive and multiply. All patients in the study were previously unresponsive to treatment with other combination therapies. Of 257 patients completing the study, the overall response rate was 24% with a median response duration of 7.4 months. The median overall survival was 15.5 months. CFZ as a standalone treatment achieved significant responses in 36% of patients who did not previously respond to treatment with bortezomib and immunomodulatory drugs, including patients with chromosomal abnormalities. CFZ was well tolerated and adverse events were manageable with no new, unexpected, or cumulative toxicities.

Survival outcomes in elderly patients with plasma cell myeloma: The three-decade Eastern Cooperative Oncology Group (ECOG) experience.

Recent landmark papers showed significant improvement in survival rates for patients under 65 years of age with plasma cell myeloma, but not for older patients. To shed new light on progress in treating older individuals, David H. Vesole, M.D., PH.D., F.A.C.P. and colleagues examined data over the last 33 years for previously untreated patients who were treated according to standard European Cooperative Oncology Group protocols during three time periods: 1988-1993, 1994-2000 and 2001-2006. Patients receiving autologous stem cell transplantation were excluded. For patients over 65 years, there was a higher overall survival in those treated 2001-2006 (39%), than in those treated 1988-1993 and 1994-2000 (2
'/>"/>

Contact: Amy Leahing
Amy.leahing@zibbel.com
John Theurer Cancer Center
Source:Eurekalert

Page: 1 2 3 4 5 6

Related biology news :

1. John Theurer Cancer Center BMT researchers highlight the importance of social support
2. Cancer stem cells recruit normal stem cells to fuel ovarian cancer, U-M study finds
3. Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients
4. UT Southwestern research reveals that significantly more genetic mutations lead to colon cancer
5. Cancer gene therapy from camels
6. Cancer data not readily available for future research
7. UT faculty improving surgical outcomes for children, cancer patients
8. Study explains why men are at higher risk for stomach cancer
9. Stem cells restore cognitive abilities impaired by brain cancer treatment
10. PSA test for men could get a second life for breast cancer in women
11. Low dose naltrexone (LDN): Harnessing the bodys own chemistry to treat human ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Infinisource has launched its new NXG series of ... G2 sets a higher standard for collecting attendance and labor ... With plug-and-play installation, touch screen interface and seamless connection to ... time collection solution for the small to mid-size employer. ...
(Date:12/22/2014)... , Dec. 22, 2014  The 2014 Holiday Season ... as Acuity Market Intelligence reports that the long anticipated ... forecasts that intensifying demand for smart phones, tablets, and ... global market of 2.5 billion users with nearly 4.8 ...
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ...
Breaking Biology News(10 mins):Infinisource's NXG series sets new time clock standard 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... led by the Karolinska Institutet, Sweden and the University of ... and the composition of human gastrointestinal bacteria. In a study ... the team outline new evidence suggesting that the human genome ... billions of microbes in the human gastrointestinal tract collectively known ...
... senior author Morris J. Birnbaum, MD, PhD, the Willard ... for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, ... works in a different way than previously understood. Their ... hormone glucagon,s ability to generate an important signaling molecule, ...
... cells in all higher organisms cells need to bind to ... tissues. Mysteries have remained, however, about exactly how cells manage ... Scripps Research Institute (TSRI) have now solved part of this ... α-catenin, which is essential to this process. The ...
Cached Biology News:International study suggests human genes influence gut microbial composition 2Most-used diabetes drug works in different way than previously thought 2New study defines the long-sought structure of a protein necessary for cell-cell interaction 2
(Date:1/23/2015)... Portal Solutions , a technology consulting firm that ... 365 and SharePoint platforms , today announces its inclusion in ... of the region’s fastest-growing mid-sized companies based on a combined ... be recognized a second year in a row by SmartCEO ...
(Date:1/22/2015)... 22, 2015  Transwestern | RBJ today announces the firm brokered ... for Shire a leading biopharmaceutical company, at Two Ledgemont Center ... Robert Richards , president, and Brian Cohen , ... entire five-floor building at 95 Hayden Ave. Photo ...
(Date:1/22/2015)... Pipette.com has added the Eppendorf Centrifuge ... of Eppendorf products. , The Eppendorf Centrifuge 5424/5424 R ... R and receive the following:, ,     Free ... Eppendorf Reference 2 ,     3 Free boxes ...
(Date:1/22/2015)... Diagenode, Inc., a leading global provider ... complete solutions for epigenetics research, recently launched a ... need for manual processing. The new ChIPettor System ... histones or transcription factors and a semi-automated pipette ...
Breaking Biology Technology:Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 2Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 3Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... most popular among makers of ... EVANSTON, Ill., Sept. 30 The ... by global sales and marketing,consulting firm ZS ... number of companies - in pharmaceutical/biotech, medical,products ...
... (Nasdaq: VRNM ), a pioneer in the ... announced today,that Janet Roemer, Executive Vice President and ... upcoming William Blair & Company 2008,Small-Cap Growth Stock ... a.m. ET on Tuesday, October 7, 2008 and ...
... Genomic,Health, Inc. (Nasdaq: GHDX ) today announced ... Officer, will present at the JMP,Securities Healthcare Focus ... at 10:00 a.m. ET., To access the ... the Investor Relations section of Genomic Health,s,website at ...
Cached Biology Technology:Quota-Based Compensation Plans Outpace Ranking Plans 2Quota-Based Compensation Plans Outpace Ranking Plans 3Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference 2Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference 3
Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
... in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and ... royalties for your hard work and endeavour! ... build it up,and market it internationally. We ...
... is causing shortages in your laboratory or ... cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us ... up,and market it internationally. We work under ...
...
Biology Products: